Evaluation of policies to support drug development in New Zealand

Health Policy

Volumn 96, Issue 2, 2010, Pages 108-117

  Lockhart, Michelle ^a   Babar, Zaheer Ud Din ^a   Garg, Sanjay ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Drug development; Health policy; Pharmaceutical industry

Indexed keywords

AUSTRALIA; CANADA; DRUG INDUSTRY; DRUG RESEARCH; GOVERNMENT; HEALTH CARE POLICY; HUMAN; INVESTMENT; MEDICAL RESEARCH; NEW ZEALAND; PATENT; PRACTICE GUIDELINE; REVIEW; UNITED KINGDOM; DRUG DEVELOPMENT; HEALTH CARE QUALITY; ORGANIZATION AND MANAGEMENT;

DRUG DISCOVERY; DRUG INDUSTRY; HEALTH POLICY; HUMANS; NEW ZEALAND; PROGRAM EVALUATION;

EID: 79952027959     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2010.01.012     Document Type: Review

References (60)

1. Achilladelis B., Antonakis N. The dynamics of technological innovation: the case of the pharmaceutical industry. Research Policy 2001, 30:535-588.
2. Verband Forschender Arznemittelhersteller e.V. [German Association of Research-based Pharmaceutical Companies]. The Pharmaceutical Industry in Germany-Statistics 2008; 2008.
3. Grabowski H. Are the economics of pharmaceutical research and development changing? Productivity, patents and political pressures. PharmacoEconomics 2004;22:15-24.
4. Mooney K.G. Challenges faced by the pharmaceutical industry: training graduates for employment in pharmaceutical R&D. European Journal of Pharmaceutical Sciences 2001, 12:353-359.
5. Schweitzer S.O. Pharmaceutical economics and policy 2007, Oxford University Press, New York.
6. Henry D., Lexchin J. The pharmaceutical industry as a medicines provider. The Lancet 2002, 360(9345):1590-1595.
7. Resnik D.B. The distribution of biomedical research resources and international justice. Developing World Bioethics 2004, 4(1):42-57.
8. Danzon P.M., Nicholson S., PereiraF N.S. Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances. Journal of Health Economics 2005, 24(2):317-339.
9. Epstein R.J. Growth of the Asian health-care market: Global implications for the pharmaceutical industry. Nature Reviews Drug Discovery 2007, 6(10):785-792.
10. Comanor W.S. The economics of research and development. Pharmaceutical innovation: incentives, competition, and cost-benefit analysis in international perspective 2007, Cambridge University Press, New York. F.A. Sloan, C.-R. Hsieh (Eds.).
11. Doran E., Henry D.A. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia. Journal of Public Health Policy 2008, 29:106-120.
12. Chataway J., Tait J., Wield D. Frameworks for pharmaceutical innovation in developing countries-the case of Indian pharma. Technology Analysis and Strategic Management 2007, 19:697-708.
13. Organisation for Economic Co-operation and Development. Reviews of Innovation Policy-New Zealand 2007; 2007.
14. Lofgren H., de Boer R. Pharmaceuticals in Australia: developments in regulation and governance. Social Science and Medicine 2004, 58:2397-2407.
15. Mossialos E., Oliver A. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. International Journal of Health Planning and Management 2005, 20:291-306.
16. Branston J.R., Rubini L., Sugden R., Wilson J.R. Healthy governance: economic policy and the health industry model. Health policy and high-tech industrial development 2005, Edward Elgar Publishing Limited UK, London. M.R. Di Tommaso, S.O. Schweitzer (Eds.).
17. Rosenberg-Yunger Z.R.S., Daar A.S., Singer P.A., Martin D.K. Healthcare sustainability and the challenges of innovation to biopharmaceuticals in Canada. Health Policy 2008, 87:359-368.
18. Sloan F.A., Hsieh C.-R. Conclusions and policy implications. Pharmaceutical innovation: incentives, competition, and cost-benefit analysis in international perspective 2007, Cambridge University Press, New York. F.A. Sloan, C.-R. Hsieh (Eds.).
19. Singh M.M. Will India become the global centre for pharmaceutical research & development?. Journal of Generic Medicines 2006, 3:194-200.
20. Chaturvedi K., Chataway J., Wield D. Policy, markets and knowledge: strategic synergies in Indian pharmaceutical firms. Technology Analysis and Strategic Management 2007, 19:565-588.
21. Ministry of Research Science and Technology, New Zealand Roadmaps science-biotechnology research: a guide for New Zealand science activity 2007, Ministry of Research Science and Technology, Wellington, p. 1-74.
22. Australian Expert Group in Industry Studies Science for life-an evaluation of New Zealand's health research investment system based on international benchmarks 2004, Australian Expert Group in Industry Studies, University of Western Sydney.
23. Yin W. Market incentives and pharmaceutical innovation. Journal of Health Economics 2008, 27:1060-1077.
24. Vogel R.J. Pharmaceutical economics and public policy 2007, Pharmaceutical Products Press, New York.
25. Sood N., De Vries H., Gutierrez I., Lakdawalla D.N., Goldman D.P. The effect of regulation on pharmaceutical revenues: experience in nineteen countries. Health Affairs 2009, 28.
26. Chaudhuri S. The gap between successful innovation and access to its benefits: Indian pharmaceuticals. European Journal of Development Research 2007, 19:49-65.
27. Cameron A., Ewen M., Ross-Degnan D., Ball D., Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. The Lancet 2009, 373:240-249.
28. Schweitzer S.O., Di Tommaso M.R. The health industry model: new roles for the health industry. Health policy and high-tech industrial development: learning from innovation in the health industry 2005, Edward Elgar Publishing, Cheltenham, UK. O. Schweitzer Stuart, R. Di Tommaso Marco (Eds.).
29. Vernon J.A. Examining the link between price regulation and pharmaceutical R&D investment. Health Economics 2005, 14:1-16.
30. Cohen J.C., Illingworth P. The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements. Developing World Bioethics 2003, 3:27-48.
31. Chaudhuri S. The WTO and India's pharmaceuticals industry: patent protection, TRIPS, and developing countries. New Delhi: Oxford University Press; 2005.
32. Business Monitor International. Singapore pharmaceuticals and healthcare report. In: International BM, editor. BMI's industry report and forecasts series. London; 2009.
33. Morgan S. The effect of evidence-based drug coverage policies on pharmaceutical R&D: a case study from British Columbia. Healthcare Policy 2008, 3.
34. Agency for Science Technology and Research. " About A*Star Research" Web. 14 May 2009. http://www.research.a-star.edu.sg/static/about.
35. Danzon P.M., Nicholson S., Pereira N.S. Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances. Journal of Health Economics 2005, 24:317-339.
36. Gelijns A.C., Thier S.O. Medical innovation and institutional interdependence: rethinking university-industry connections. Journal of the American Medical Association 2002, 287:72-77.
37. Parmar H. Biotechnology in India: emerging opportunities. Journal of Commercial Biotechnology 2005, 12:61-66.
38. Entzeroth M. Editorial: Singapore-creation of a scientific in Southeast Asia. Biotechnology Journal 2007, 1315-1316.
39. Thorsteinsdóttir H. The role of the health system in health biotechnology in developing countries. Technology Analysis and Strategic Management 2007, 19:659-675.
40. Pharmaceuticals Industry Strategy Group. PISG Directions Paper; 2008.
41. Department of Health U Best research for best health-a new national health research strategy 2006, Department of Health, UK, London. Department of Health U (Ed.).
42. Lakdawalla D.N., Goldman D.P., Michaud P.C., Sood N., Lempert R., Cong Z., et al. U.S. pharmaceutical policy in a global marketplace. Health Affairs 2009, 28.
43. FDA. Cumulative list of all products that have received orphan designation; 17 December 2008. http://www.fda.gov/orphan/designat/list.htm.
44. Jommi C., Paruzzolo S. Public administration and R&D localisation by pharmaceutical and biotech companies: a theoretical framework and the Italian case-study. Health Policy 2007, 81:117-130.
45. Garattini L., Cornago D., De Compadri P. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy 2007, 82:330-339.
46. Siva N. The drug price is right-or is it?. The Lancet 2009, 373:1326-1327.
47. Australian Government, Department of Health and Ageing. National Medicines Policy; 1999.
48. Department of Industry Tourism and Resources, New Zealand Pharmaceuticals industry action agenda-discussion paper 2001, Department of Industry, Tourism and Resources, Wellington. Section P (Ed.).
49. Organisation for Economic Co-operation and Development OECD Science, Technology and Industry Scoreboard 2007 2007, OECD Science, Technology and Industry Scoreboard. OECD (Ed.).
50. McDonald K. Australian snapshot. Australian Life Scientist; 2008.
51. Rankin J., Mason J., Kottege N., Anderssen N.Y. Clinical trials of unapproved medicines in Australia. The Medical Journal of Australia 2006, 185:342-343.
52. Cohen J.C. Expanding drug access in Brazil: lessons for Latin America and Canada. Canadian Journal of Public Health 2006, 97.
53. Open University: Building the case for national system of health innovation Jan 2007. 1-48. (accessed 5/2/2010). http://oro.open.ac.uk/10978/.
54. Singh R. Clinical research in China and India: a paradigm shift in drug development. Drug Discovery Today 2006, 11:675-676.
55. Faunce T., Shats K. Bilateral trade agreements as drivers of national and transnational benefit from health technology policy: implications of recent US deals for Australian negotiations with China and India. Australian Journal of International Affairs 2008, 62:196-213.
56. Glickman S.W., McHutchison J.G., Peterson E.D., Cairns C.B., Harrington R.A., Califf R.M., et al. Ethical and Scientific Implications of the Globalization of Clinical Research. N Engl J Med 2009, 360(8):816-823.
57. Frew S., Kettler H., Singer P.A. The Indian and Chinese health biotechnology industries: Potential champions of global health?. Health Affairs 2008, 27(4):1029-1041.
58. Kaplan W., Laing R. Local production of pharmaceuticals: industrial policy and access to medicines. Health, Nutrition and Population 2005, 1-54.
59. Organisation for Economic Co-operation and Development [OECD]. Pharmaceutical pricing policies in a global market; 2008.
60. Smith R.D., Correa C., Oh C., Trade TRIPS, and pharmaceuticals. The Lancet 2009, 373:684-691.